Every AXLRx Breast Cancer HR+/HER2- report, across 9 report types and 2 markets. Each is scoped to your asset and verified to a live source.
First-line HR+/HER2- metastatic disease is a three-way CDK4/6-inhibitor contest, but only ribociclib has posted consistent overall-survival wins (63.9 vs 51.4 months in MONALEESA-2, HR 0.76). The real competition has moved downstream, where 2023 approvals of an oral SERD and an AKT inhibitor carve the post-CDK4/6 line by biomarker.
HR+/HER2- is the largest breast cancer subtype, roughly 68% of the estimated 317,000 new US invasive female cases in 2025. Most present early and are curable, but 20-30% recur to metastatic disease where five-year survival falls to about a third, making biomarker testing (ESR1, PIK3CA) the fork that determines the treatment path.
US access to HR+/HER2- oral therapies runs through Medicare Part D and commercial prior authorization, and the price ceiling is now being set directly by the government: palbociclib was selected for Medicare negotiation with a 50% cut ($15,741 to $7,871) effective 2027. Newer targeted agents face biomarker-gated coverage and cost-effectiveness ratios far above accepted thresholds.
A single five-centre South West England consortium tracks 666 UK patients across all three approved CDK4/6 inhibitors. That kind of coordinated, multi-centre evidence generation is exactly the institutional signal this workbook sizes before any individual name enters it.
NICE accepts palbociclib, ribociclib, and abemaciclib as comparators for each other. No trial has ever tested any of them head-to-head against exemestane plus everolimus, the older endocrine-based comparator regimen they effectively replaced.
316,950 annual US invasive breast cancer diagnoses and a 6.0% metastatic-at-diagnosis rate size the incident flow. Layering CDK4/6-inhibitor and post-progression pricing onto that flow, and onto the separate, larger recurrence pool, is what turns a patient count into a market value.
The post-CDK4/6 line in HR+/HER2- metastatic breast cancer is fragmented by biomarker, and elacestrant's own cost-effectiveness analysis found it 58 times above the standard willingness-to-pay threshold. That precedent is the bar a new targeted entrant must clear.
A 9,146-patient US real-world study found no significant survival difference between palbociclib, ribociclib, and abemaciclib. When the drugs perform equivalently, KOL guidance decides which one gets prescribed, not clinical data.
Ibrance's Medicare-negotiated price takes effect a full year before Kisqali's and Verzenio's. Three clinically equivalent drugs, staggered IRA negotiation cycles, means Pfizer sets the reference point Novartis and Lilly then have to negotiate against.
316,950 new US invasive breast cancer diagnoses in 2025. Only 6.0% present as metastatic at diagnosis, but 73.9% of the metastatic population is HR+/HER2-, the subtype this model is actually built to size.
AXLRx publishes Competitive Intelligence, Disease Landscape, Payer & HTA, KOL Mapping, HTA Strategy Model, Market Sizing Model, Launch Readiness, Pricing Strategy Model, and Patient Flow Model for Hormone receptor-positive, HER2-negative breast cancer. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Breast Cancer HR+/HER2- coverage spans United States and United Kingdom. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Breast Cancer HR+/HER2- reports were updated July 2026.